Bristol-Myers Squibb
Blood clot fears halt cancer trial enrolment
February 3, 2011Research and Development BMS, Bristol-Myers Squibb, Eli Lilly, NSCLC, lilly, necitumumab, non small cell lung cancer, non-small cell lung cancer
Lilly and BMS have stopped enrolment in a phase III trial of necitumumab, a new treatment for non-small cell lung …
NICE decides to back Abilify in schizophrenia
January 27, 2011Sales and Marketing Abilify, BMS, Bristol-Myers Squibb, NICE, Otsuka, aripiprazole, schizophrenia
NICE has changed its mind over Bristol-Myers Squibb’s and Otsuka Pharmaceuticals Abilify, deciding to recommend the drug as a schizophrenia …
BMS and Sanofi recall 64 million Avalide tablets
January 18, 2011Manufacturing and Production Avalide, Avapro, Bristol-Myers Squibb, GMP, Good Manufacturing Practice, Sanofi-Aventis, hypertension, irbesartan
Bristol-Myers Squibb and Sanofi-Aventis have started another massive recall of their antihypertensive product Avalide because a manufacturing defect could affect …
BMS appoints Dr Veronique Walsh
January 5, 2011Sales and Marketing BMS, Bristol-Myers Squibb, Dr Véronique Walsh, appointment, sales and marketing
Bristol-Myers Squibb UK has appointed Dr Véronique Walsh as business unit director, neuroscience and immunoscience . She joins the company …
VTE trial boost for Pfizer and BMS’ apixaban
December 31, 2010Research and Development, Sales and Marketing BMS, Bristol-Myers Squibb, Pfizer, VTE, apixaban, enoxaparin, venous thromboembolism
Pfizer and Bristol-Myers Squibb’s oral anticoagulant apixaban has shown benefits over a standard injectable treatment for venous thromboembolism in a …
BMS licences phase II HIV compound festinavir
December 22, 2010Research and Development BMS, Bristol-Myers Squibb, HIV, NRTI, Oncolys BioPharma, festinavir, nucleoside reverse transcriptase inhibitor
Bristol-Myers Squibb is to pay hundreds of millions of dollars to a Japanese biotech firm to get its hands on …
Bristol-Myers Squibb appoints new UK general manager
December 13, 2010Manufacturing and Production, Research and Development, Sales and Marketing Amadou Diarra, BMS, Bristol-Myers Squibb, appointment, recruitment, sales and marketing
Bristol-Myers Squibb has appointed Amadou Diarra as general manager of its UK company, where he will be in charge of …
NICE limits access to cancer drugs, study confirms
November 10, 2010Sales and Marketing BMS, Bristol-Myers Squibb, Cancer, Cancer Drugs Fund, IPSOR, Maximilian Lebmeier, NICE, hta
NICE became more restrictive in its assessment of new cancer drugs between 2007 and 2009, a new report suggests. The …
BMS skin cancer drug hits US regulatory delay
November 3, 2010Research and Development BMS, Bristol-Myers Squibb, FDA, MDX010-020 trial, ipilimumab, skin cancer
US regulators have announced they need more time to assess Bristol-Myers Squibb’s skin cancer treatment ipilimumab. The FDA will not …
BMS faces approval block unless GMP issues are resolved
November 2, 2010Manufacturing and Production BMS, Bristol-Myers Squibb, FDA, Puerto Rico, belatacept, manufacturing compliance, pharma manufacturing
Bristol-Myers Squibb has been threatened with a block on approvals of certain new drugs, including a biologic for preventing organ …
Pharma manufacturing news in brief
October 26, 2010Manufacturing and Production AMRI, BASF, BMS, Bend Research, Bristol-Myers Squibb, Parmetics, Stirling Pharma, Vical, pharma manufacturing
This week’s round-up of pharmaceutical manufacturing news features updates from Pharmetics, AMRI, Bend Research/BMS, Stirling Pharma, Vical and BASF. A …
Latest content
